AFX.DE Carl Zeiss Meditec (XETRA) €28.20 pre-market before 12 Feb earnings: focus on guidance

AFX.DE stock trades at €28.20 in pre-market on XETRA as investors position ahead of Carl Zeiss Meditec AG’s earnings due 12 Feb 2026. The company reports results after markets close in Germany, and guidance or margin commentary could move shares. Current metrics show a PE of 17.52 and EPS of 1.61, while year high is €71.65 and year low is €26.94. We outline what to watch, how valuation compares to peers, and where Meyka AI’s models place the stock.

AFX.DE stock: earnings timing and what to expect

Carl Zeiss Meditec (AFX.DE) reports on 12 Feb 2026, with results due after trading in Germany on XETRA. Expect commentary on Ophthalmic Devices sales and Microsurgery orders, plus updated guidance on margins. Analysts will watch recurring consumables revenue and backlog trends for cataract systems, which drive near-term profitability.

Valuation snapshot and recent performance for AFX.DE stock

At €28.20, Carl Zeiss Meditec’s PE is 17.52 and market cap is €2,468,517,428.00. The 50-day average is €37.35 and the 200-day average is €46.27, showing a clear downtrend. Year-to-date the share price is down 28.75% and the one-year change is down 50.79%, underlining valuation reset risk ahead of earnings.

Growth, margins and cash metrics investors should read

Latest fiscal metrics show revenue per share €25.45 and net income per share €1.61, with free cash flow yield near 5.84%. R&D spend is 18.30% of revenue, supporting product pipeline but pressuring margin near term. The current ratio is 2.35, and interest coverage is 7.39, which supports liquidity through cycles.

Technical picture and trading liquidity for AFX.DE stock

Volume pre-market is light versus average, at 268,986 today vs average 309,407, so moves may be amplified. Price sits below Bollinger middle at €41.12 and 50-day at €37.35, indicating bearish momentum. RSI near 55.97 shows mixed momentum, so earnings reaction could drive a sharp intraday swing.

Meyka AI grade, forecast and price targets for AFX.DE stock

Meyka AI rates AFX.DE with a score out of 100: 73.81 (B+) with a suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €36.00, implying 27.66% upside from €28.20. Conservative target €25.00 implies -11.34% downside, while bull case €45.00 implies 59.57% upside. Forecasts are model-based projections and not guarantees.

Key risks and catalysts shaping the AFX.DE stock outlook

Near-term risks include weaker consumables demand, margin compression from pricing, and supply-chain delays in surgical systems. Catalysts are clearer guidance, stronger U.S. procedure volumes, and margin recovery from cost actions. Watch management tone on buyback or dividend policy changes as potential positive catalysts.

Final Thoughts

Key takeaways for AFX.DE stock ahead of earnings: shares trade at €28.20 on XETRA and the set-up favours volatility when Carl Zeiss Meditec reports on 12 Feb 2026. Fundamentals show decent liquidity and a PE of 17.52, but the share price sits well below 50- and 200-day averages, reflecting a recent re-rating. Meyka AI’s model projects a €36.00 12-month target, an implied 27.66% upside versus the current price, while a conservative target of €25.00 suggests downside risk. Investors should weigh guidance clarity, consumables trends, and margin commentary in the report. Remember, Meyka AI is an AI-powered market analysis platform and forecasts are model-based projections and not guarantees. For those tracking trading strategies, a clear beat on revenue and improved margin guidance would likely trigger a technical reversal toward €37.00 resistance, while a weak print could test the €26.94 year low. Consider position sizing to manage event-driven volatility.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.